CVRx preliminary Q4 rev $3.6-3.7M (+71-77% YoY); FY2021 rev $13.0-13.1M (+113-116% YoY); FY2022 guidance $20-23M

CVRx, Inc.

2022-FY EPS reported -$4.16 revenue$13,036,000

Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.
Full year 2021 revenue $13.0-$13.1M, up 113-116% from $6.1M in 2020.
U.S. heart failure revenue $8.4M, Europe $3.9M, U.S. legacy $0.7M for 2021.
Active implanting centers grew to 46 as of Dec 31, 2021 from 38 as of Sep 30, 2021.
FY2022 revenue guidance $20-$23M; Q1 2022 expected $3.6-$4.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.